only in CYC-treated RMD patients who receive CYC monthly by intravenous administration. Acknowledging this lack of data on oral CYC-treated patients, it is reasonable to consider gonadotropin-releasing hormone agonist use for these patients. Theoretically, gonadotropin-releasing hormone agonist co-therapy may not be necessary for patients receiving the lower cumulative CYC dose in the Euro-Lupus regimen Fertility preservation in men with RMD treated with CYC. CYC may cause infertility and